Antibodies involved in our recent developments

These antibodies represent advancements across various therapeutic areas, highlighting the versatility and potential of antibody-based approaches in improving patient care and outcomes.

Checkpoint Inhibitor Antibodies:

Antibodies targeting immune checkpoint proteins such as PD-1, PD-L1, and CTLA-4 have revolutionized cancer immunotherapy by unleashing the body's immune system to attack cancer cells.

Monoclonal Antibodies for COVID-19:

Antibodies such as REGN-COV2 (casirivimab and imdevimab) and bamlanivimab/etesevimab have been developed for the treatment of COVID-19, showing promising results in reducing the severity of illness and hospitalization rates.

Bispecific Antibodies:

Bispecific antibodies, which can simultaneously bind to two different targets, are gaining traction in the field of cancer therapy and immune modulation. Examples include blinatumomab (for acute lymphoblastic leukemia) and catumaxomab (for malignant ascites).

Anti-CD19 CAR-T Cell Therapy Antibodies:

Antibodies targeting CD19, such as tisagenlecleucel and axicabtagene ciloleucel, are used in chimeric antigen receptor (CAR) T cell therapy for the treatment of certain types of leukemia and lymphoma.

Anti-HER2 Antibodies:

Antibodies targeting the human epidermal growth factor receptor 2 (HER2), such as trastuzumab and pertuzumab, have transformed the treatment of HER2-positive breast cancer and gastric cancer.

Anti-CD20 Antibodies:

Antibodies targeting CD20, such as rituximab, obinutuzumab, and ofatumumab, are widely used in the treatment of B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Anti-VEGF Antibodies:

Antibodies targeting vascular endothelial growth factor (VEGF), such as bevacizumab and aflibercept, are used in the treatment of various cancers, including colorectal cancer, lung cancer, and glioblastoma.

Anti-TNF Antibodies:

Antibodies targeting tumor necrosis factor alpha (TNF-alpha), such as infliximab, adalimumab, and etanercept, are used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis.

Anti-IL-6 Antibodies:

Antibodies targeting interleukin-6 (IL-6), such as tocilizumab and sarilumab, have shown efficacy in the treatment of cytokine release syndrome associated with CAR-T cell therapy and inflammatory conditions such as rheumatoid arthritis.

Anti-CD38 Antibodies:

Antibodies targeting CD38, such as daratumumab and isatuximab, have emerged as effective therapies for multiple myeloma, both as monotherapy and in combination with other agents.

These antibodies represent just a snapshot of the diverse landscape of antibody-based therapeutics and diagnostics, with ongoing research and development continually expanding the repertoire of available options.

AffiGEN Inc's Innovative Approach in Antibody Development